LifeStance Health (LFST) Upgraded to Strong Buy: Here's What You Should Know
LifeStance Health (LFST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 37.26% Upside in LifeStance Health (LFST): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 37.3% in LifeStance Health (LFST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Bears are Losing Control Over LifeStance Health (LFST), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for LifeStance Health (LFST), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
LifeStance Health Group, Inc. (LFST) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
LifeStance Health Group, Inc. (LFST) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Earnings Estimates Rising for LifeStance Health (LFST): Will It Gain?
LifeStance Health Group (LFST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
LifeStance Health Group (LFST) is a Great Momentum Stock: Should You Buy?
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 31.02% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
The consensus price target hints at a 31% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LifeStance Health Group Q1 Earnings Call Highlights
LifeStance Health Group NASDAQ: LFST reported first-quarter 2026 results that management said exceeded expectations and prompted the company to raise full-year guidance across its key metrics. On the company's earnings call, CEO Dave Bourdon highlighted what he described as an “exceptional start to the year,” pointing to revenue growth of more than 21% and adjusted EBITDA topping $50 million.
LifeStance Health Group, Inc. (LFST) Q1 2026 Earnings Call Transcript
LifeStance Health Group, Inc. (LFST) Q1 2026 Earnings Call Transcript
LifeStance Health Group, Inc. (LFST) Q4 2025 Earnings Call Transcript
LifeStance Health Group, Inc. (LFST) Q4 2025 Earnings Call Transcript
LifeStance Health Group (LFST) Q4 Earnings and Revenues Top Estimates
LifeStance Health Group (LFST) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.02 per share a year ago.
Wall Street Analysts Think LifeStance Health (LFST) Could Surge 30.49%: Read This Before Placing a Bet
The mean of analysts' price targets for LifeStance Health (LFST) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
